INGN vs LFCR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
INGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position with a Current Ratio of 3.12 and very low debt (D/E 0.09), it is unable to translate this into profitability, as evidenced by negative operating margins and stagnant revenue growth of 2%. There is a stark disconnect between the 'Strong Buy' analyst consensus and the fundamental reality of a 5-year price collapse of 88.6%. The stock currently presents as a classic value trap, trading below book value but lacking the growth catalysts necessary for a reversal.
LFCR presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of valuation anchors like the Graham Number or Intrinsic Value. While the company shows strong short-term liquidity (Current Ratio 3.49) and positive Q/Q revenue growth, these are overshadowed by a critical negative book value (P/B -12.53) and excessive leverage (Debt/Equity 4.15). The technical trend is aggressively bearish (0/100), and the historical earnings track record is marked by extreme volatility and frequent misses.
Compare Another Pair
Related Comparisons
INGN vs LFCR: Head-to-Head Comparison
This page compares Inogen, Inc. (INGN) and Lifecore Biomedical, Inc. (LFCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.